Promotional material submissions are the odd one out in regulatory operations. The content is produced by commercial teams, reviewed under a medical-legal-regulatory process that has nothing to do with eCTD, and then — at the last moment — has to be published and transmitted as a properly structured electronic submission like any other sequence.
Since June 2021, that last step has been mandatory in eCTD format. The structure is described in FDA’s final guidance Providing Regulatory Submissions in Electronic and Non-Electronic Format — Promotional Labeling and Advertising Materials for Human Prescription Drugs, published 24 June 2019. What follows is a practical walk through where things go, because the single most common cause of a rejected or mis-filed promotional submission is putting the right document in the wrong heading.
The three things every 2253 submission contains
A postmarketing promotional submission under Form FDA 2253 has three required components. Everything else is optional or situational:
- A completed Form FDA 2253 — the Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use
- The current product labeling for the promoted product
- A clean copy of the promotional material itself
That list looks trivial. The difficulty is that those three items live in three different parts of Module 1, none of them adjacent, and two of them in headings that most publishing teams rarely touch outside of promotional work.
Where each component goes
| Component | eCTD heading | Notes |
|---|---|---|
| Form FDA 2253 | 1.1 (Forms) | Sits alongside other agency forms, not with the promotional content |
| Current product labeling | 1.14.6 | Product labeling for 2253 submissions; a cross-reference may be used if previously submitted |
| Promotional material | 1.15.2 | Under the promotional material heading, split by audience |
The split matters. Regulatory operations staff coming from an NDA or BLA background will instinctively look for a single folder holding “the promotional submission.” There isn’t one. The form is filed as a form, the labeling is filed as labeling, and only the material itself sits under the promotional heading.
Module 1.15 is not a flat folder
Section 1.15 carries structure of its own. The promotional material heading is qualified by intended audience — professional or consumer — and beneath it, section 1.15.2 holds the materials for a 2253 submission. Each individual material then gets its own node carrying its own attributes, including a material ID and an issue date, with the clean version of the file underneath.
In practice the hierarchy reads something like:
m1-15-promotional-material(audience: professional)- →
m1-15-2-materials(promotional 2253) - →→
m1-15-2-1-material— with the material type, material ID and issue date as attributes - →→→
m1-15-2-1-1-clean-version— the actual file
Two consequences follow from this that catch teams out. First, the material ID is submission metadata, not a filename convention — it belongs in the eCTD attributes and needs to match whatever identifier the commercial team uses on the piece. Second, one submission can carry many materials, each with its own node, its own ID and its own issue date. A promotional submission is closer to a container of independently identified artifacts than to a single document package.
The other submission types share the same skeleton
Form 2253 postmarketing submissions are the highest-volume case, but they are not the only one. The same Module 1.15 area also handles:
- Requests for advisory comments, including launch materials and the correspondence that precedes approval
- Accelerated approval submissions under 21 CFR 314.550, where materials are provided for review before dissemination
- Responses to OPDP correspondence, which have their own heading within 1.15.1
Because these share the assembly path, teams that treat 2253 publishing as a one-off script usually end up rewriting it the first time an advisory request or an accelerated approval product appears. It is worth designing the submission-type handling to be polymorphic from the start.
Technical details that are easy to get wrong
- Regional DTD version. Promotional submissions should use
us-regional-v3-3.dtdor higher. Older backbones will fail validation. - Draft versus current labeling. A 2253 submission carries the current approved labeling. Draft labeling is only appropriate for accelerated approval and advisory submissions, where the product is not yet approved.
- Cross-references for labeling. If the current labeling has already been submitted, you may cross-reference it under 1.14.6 rather than re-submitting a PDF. This is a genuine saving on high-volume promotional programmes, but it depends on the previous submission being findable and current.
- Audience matters. Professional and consumer materials sit under different qualifications of 1.15. Filing a direct-to-consumer piece under the professional heading is a structural error, not a metadata nicety.
Why this is a publishing problem, not a marketing problem
The organisational trap is that promotional material feels like it belongs to commercial. The MLR review that produces an approved piece is a commercial and legal process, and the people who run it usually have no eCTD tooling at all. But the moment the piece is approved, the obligation becomes a regulatory publishing obligation with a hard deadline attached — the material must reach FDA at the time of initial dissemination.
Teams that hand the finished PDF to regulatory operations at the last minute discover that assembling a valid sequence, validating it and transmitting it through the gateway is not a five-minute task. Teams that treat promotional submissions as a first-class publishing workflow — with the structure above encoded once, rather than rebuilt per piece — spend far less time on them and reject far fewer.
Primary sources
Verify everything above against the current versions of these before you build anything on it:
- FDA guidance: Providing Regulatory Submissions in Electronic and Non-Electronic Format — Promotional Labeling and Advertising Materials for Human Prescription Drugs
- OPDP eCTD resource page — structure requirements, recorded webinars and how-to material
- Comprehensive Table of Headings for eCTD Module 1
DnXT builds eCTD publishing, validation and dossier review software for regulatory operations teams. This article is general information about FDA requirements, not regulatory advice — verify every detail against the current FDA guidance and forms before you rely on it.
